Periurethral fibrosis secondary to prostatic inflammation causing lower urinary tract symptoms: a prospective cohort study.
暂无分享,去创建一个
[1] J. Hollingsworth,et al. Prostatic fibrosis is associated with lower urinary tract symptoms. , 2012, The Journal of urology.
[2] R. Hayes,et al. Non‐steroidal anti‐inflammatory drug use and the risk of benign prostatic hyperplasia‐related outcomes and nocturia in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial , 2012, BJU international.
[3] T. Nguyen,et al. Hexanic lipidosterolic extract of Serenoa repens inhibits the expression of two key inflammatory mediators, MCP‐1/CCL2 and VCAM‐1, in vitro , 2012, BJU international.
[4] G. Norstedt,et al. Androgen‐independent Effects of Serenoa repens Extract (Prostasan®) on Prostatic Epithelial Cell Proliferation and Inflammation , 2012, Phytotherapy research : PTR.
[5] F. Schröder,et al. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. , 2011, European urology.
[6] S. Terry,et al. Inflammation in benign prostatic hyperplasia: A 282 patients' immunohistochemical analysis , 2009, The Prostate.
[7] Y. Allory,et al. Should We Investigate Prostatic Inflammation for the Management of Benign Prostatic Hyperplasia , 2009 .
[8] Marco Bianchi,et al. Benign Prostatic Hyperplasia and Its Aetiologies , 2009 .
[9] E. Platz,et al. Anti-inflammatory drugs, antioxidants, and prostate cancer prevention. , 2009, Current opinion in pharmacology.
[10] L. Adorini,et al. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. , 2009, International journal of andrology.
[11] M. Gyetko,et al. Recent advances in molecular targets and treatment of idiopathic pulmonary fibrosis: focus on TGFbeta signaling and the myofibroblast. , 2009, Current medicinal chemistry.
[12] D. Bostwick,et al. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. , 2008, European urology.
[13] H. Ellingsgaard,et al. Islet Inflammation in Type 2 Diabetes , 2008, Diabetes Care.
[14] A. Sciarra,et al. Inflammation and chronic prostatic diseases: evidence for a link? , 2007, European urology.
[15] H. Hoshi,et al. Comparison of urethral diameters for calculating the urethral dose after permanent prostate brachytherapy , 2007, Radiation Medicine.
[16] G. Kramer,et al. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? , 2007, European urology.
[17] J. S. St. Sauver,et al. Protective association between nonsteroidal antiinflammatory drug use and measures of benign prostatic hyperplasia. , 2006, American journal of epidemiology.
[18] B. Sipos,et al. Pancreatic fibrosis associated with age and ductal papillary hyperplasia , 2005, Virchows Archiv.
[19] C. Roehrborn,et al. 1277: The Impact of Acute or Chronic Inflammation in Baseline Biopsy on the Risk of Clinical Progression of BPH: Results from the MTOPS Study , 2005 .
[20] D. Peehl,et al. Molecular and cellular pathogenesis of benign prostatic hyperplasia. , 2004, The Journal of urology.
[21] A. Farré,et al. BPH and inflammation: pharmacological effects of Permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay. , 2003, European urology.
[22] A. Sciarra,et al. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. , 2003, European urology.
[23] Downey,et al. Asymptomatic inflammation and/or infection in benign prostatic hyperplasia , 1999, BJU international.
[24] J. Goujon,et al. Inflammation in benign prostatic hyperplasia: correlation with prostate specific antigen value. , 1997, The Journal of urology.
[25] W. Schäfer,et al. Principles and clinical application of advanced urodynamic analysis of voiding function. , 1990, The Urologic clinics of North America.
[26] S. Kaplan,et al. Role of inflammation in benign prostatic hyperplasia. , 2011, Reviews in urology.
[27] C. Bosman,et al. Combination Therapy with Rofecoxib and Finasteride in the Treatment of Men with Lower Urinary Tract Symptoms (LUTS) and Benign Prostatic Hyperplasia (BPH) , 2005 .
[28] P. Abrams,et al. The Abrams-Griffiths nomogram , 2004, World Journal of Urology.
[29] T. Koyanagi,et al. Difference of cancer core distribution between first and repeat biopsy: In patients diagnosed by extensive transperineal ultrasound guided template prostate biopsy , 2004, The Prostate.
[30] P. Abrams,et al. Good urodynamic practices: Uroflowmetry, filling cystometry, and pressure‐flow studies * * , 2002, Neurourology and urodynamics.